Jim Cramer On Valeant: It's Not a Good Short

Jim Cramer noted that Valeant Pharmaceuticals (VRX)  shares have fallen so much, that there are no sellers. "It's like everyone who's left is saying they're willing to own it," he said. 

Jim Cramer and Real Money columnists discuss the latest from President Donald Trump and the GOP efforts to repeal and replace the Affordable Care Act. See which stocks they are discussing and get his insights or analysis with a free trial subscription to Real Money.

Top news on TheStreet today:

• Valeant Shows Signs Its Turnaround Efforts Are Bearing Fruit; Jim Cramer Weighs In
• Alibaba Launches AliPay in U.S. to Challenge WeChat, Apple Pay
• Amazon Just Released a New Echo Device With a Touchscreen
• Jim Cramer Is Watching Disney's Earnings on Tuesday
• Walgreens Gives FTC Deadline on Rite Aid Ruling

This article was written by a staff member of TheStreet.